基于网络药理学探讨金欣口服液治疗新型冠状病毒肺炎的潜在作用机制  

Network Pharmacology of Jinxin Oral Liquid in the Treatment of COVID-19

作　　者：何钰 许海燕[2] 单进军 赵霞 沈存思 纪建建 林丽丽 杨瑞 谢彤 汪受传 HE Yu;XU Hai-yan;SHAN Jin-jun;ZHAO Xia;SHEN Cun-si;JI Jian-jian;LIN Li-li;YANG Rui;XIE Tong;WANG Shou-chuan(Jiangsu Key Laboratory for Pediatric Respiratory Disease, Nanjing University of Chinese Medicine, Nanjing, 210023, China;Microbiological Laboratory, Nantong Center for Disease Control and Prevention,Nantong,226007, China)

机构地区：[1]南京中医药大学,江苏省儿童呼吸疾病(中医药)重点实验室,江苏南京210023 [2]南通市疾病预防控制中心微生物检验科,江苏南通226007

出　　处：《南京中医药大学学报》2020年第3期295-299,共5页Journal of Nanjing University of Traditional Chinese Medicine

基　　金：江苏省自然科学基金(BK20181426);江苏省高等学校自然科学研究重大项目(18KJA360004);江苏省研究生科研与实践创新计划(SJKY19_1457)。

摘　　要：目的采用网络药理学方法探究金欣口服液治疗新型冠状病毒肺炎的可能性和潜在作用靶点。方法利用中药系统药理学数据库与分析平台(TCMSP)筛选金欣口服液的物质组成分,以口服生物吸收度和成药相似性为限制条件筛选类药性成分及其作用靶点。以规范化的MeSH主题词搜索疾病相关的靶点基因,并对靶点进行蛋白交互作用分析。进一步利用DAVID数据库进行基因本体分析,以类药性成分→基因靶点→作用通路的交互网络分析金欣口服液治疗新型冠状病毒肺炎的可能效应成分和潜在作用靶点。结果金欣口服液中筛选得到129种类药性成分,以苯丙素和脂类成分为主。筛选到类药成分作用于病毒性肺炎相关的靶点基因75个,基因本体分析和交互网络分析结果显示其黄酮类成分和脂质类成分具有抗病毒免疫和抗炎作用。结论金欣口服液具有潜在的抗新型冠状病毒肺炎的作用。OBJECTIVE The network pharmacology was used to explore the targets of Jinxin oral Liquid in the treatment of COVID-19.METHODS TCMSP database was used to mining the drug-like components in Jinxin oral Liquid and corresponding targets.The targets of pneumonia-related diseases in DisGeNET library was pointed and matched to the components'targets.STRING database was used for protein interaction network diagram.The DAVID website was used for further gene ontology analysis.RESULTS A total of 129 drug like compounds were obtained.Totally,75 gene targets were matched to drug like components and pneumonia-related diseases.Protein interaction and gene ontology analysis suggested that the antiviral immune response and anti-inflammatory responses are most enriched.CONCLUSION The components in Jinxin oral Liquid were the possible candidates for treatment of COVID-19.

关 键 词：金欣口服液 网络药理学 新型冠状病毒肺炎 

分 类 号：R285.5[医药卫生—中药学]